Skip to main content

Table 2 Treatment schedules

From: Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

A) BZB treatment Number of patients (number of drug administrations)

Treatment schedule

Number of drug administrations for different dosages

 Induction only

Induction + maintenance

Induction schedule (HCP number)

Maintenance range

5 mg/kg

2.5 mg/kg

1 mg/kg

 38 (228)

31 (481)

Every 3 wks (3)

Every 2 wks (3)

Every 4–12 weeks

669

4

36

B) TH treatment Months of treatment in 67 patients

Pts with daily dosage < 50 mg

Pts with daily dosage 50 mg

Pts with daily dosage 100 mg

Pts with daily dosage 200 mg

Pts/Mean daily dosagea

 900

31

26

2

2

5/90

1/150

  1. Legend: ain patients treated with different dosages along the treatment